Curis Announces New Preclinical Data for CI-8993 at the Society for Immunotherapy of Cancer (SITC) Annual MeetingPRNewsWire • 11/09/21
Curis Announces First Patient Dosed in Phase 1/2 Study of CA-4948 Combination Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromesPRNewsWire • 11/08/21
Curis to Release Third Quarter 2021 Financial Results and Hold Conference Call on November 9, 2021PRNewsWire • 11/02/21
Curis Announces New Preclinical Data Highlighting the Potential of CA-4948 in Multiple Hematologic Malignancies Presented at the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer TherapeuticsPRNewsWire • 10/07/21
Will Curis (CRIS) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 07/27/21
Curis to Release Second Quarter 2021 Financial Results and Hold Conference Call on August 3, 2021PRNewsWire • 07/27/21
Curis Announces Positive Updated Data from Ongoing Phase 1/2 Study of CA-4948 Monotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic SyndromesPRNewsWire • 06/11/21
Curis to Host Virtual Event to Discuss Updated Clinical Data for CA-4948 in AML/MDS Presented at EHAPRNewsWire • 06/04/21
Curis, Inc. Announces 2021 Virtual Symposium: "VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond"PRNewsWire • 06/01/21
Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing EstimatesBenzinga • 05/13/21